[미국특허]
Long-acting coagulation factors and methods of producing same
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-014/00
C07K-016/00
A61K-038/00
C12N-009/50
C07K-014/505
C07K-014/59
C07K-014/745
C12N-009/64
A61K-047/64
출원번호
US-0159641
(2016-05-19)
등록번호
US-10144921
(2018-12-04)
발명자
/ 주소
Fima, Udi Eyal
Hart, Gili
출원인 / 주소
OPKO Biologics Ltd.
대리인 / 주소
Cohen, Mark S.
인용정보
피인용 횟수 :
0인용 특허 :
79
초록▼
Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polyn
Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
대표청구항▼
1. A CTP-modified polypeptide consisting of a coagulation factor and three to five chorionic gonadotropin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said coagulation factor, wherein optionally a signal peptide is attached to the amino terminus of said coagulation factor, wh
1. A CTP-modified polypeptide consisting of a coagulation factor and three to five chorionic gonadotropin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said coagulation factor, wherein optionally a signal peptide is attached to the amino terminus of said coagulation factor, wherein at least one CTP is optionally attached to the coagulation factor via a linker, and wherein said coagulation factor is selected from Factor VII (FVII) and activated Factor VII (FVIIa). 2. The CTP-modified polypeptide of claim 1, wherein the sequence of at least one CTP is selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2. 3. The CTP-modified polypeptide of claim 1, wherein at least one CTP is glycosylated. 4. The CTP-modified polypeptide of claim 1, wherein at least one CTP is truncated. 5. The CTP-modified polypeptide of claim 1, wherein said linker is a peptide bond. 6. The CTP-modified polypeptide of claim 1, wherein the sequence of said CTP-modified Factor VII (FVII) or activated Factor VII (FVIIa) is set forth in SEQ ID NO: 46. 7. The CTP-modified polypeptide of claim 1, wherein said polypeptide has a signal peptide. 8. The CTP-modified polypeptide of claim 7, wherein said signal peptide is set forth in SEQ ID NO: 47. 9. The CTP-modified polypeptide of claim 7, wherein the sequence of said CTP-modified FVII is set forth in SEQ ID No: 25. 10. A pharmaceutical composition comprising the CTP-modified polypeptide of claim 1 and a pharmaceutically acceptable carrier. 11. The CTP-modified polypeptide of claim 1, wherein said activated FVII (FVIIa) polypeptide is in the form of a disulfide-linked two chain heterodimer, wherein said two chains comprise a light chain consisting of amino acids 1-152 and a heavy chain consisting of amino acids 153-490 of SEQ ID NO: 46. 12. A method of extending the biological half-life of a coagulation factor, comprising the step of attaching three to five chorionic gonadotropin carboxy terminal peptides (CTPs) to the carboxy terminus of said coagulation factor, thereby extending the biological half-life of said coagulation factor, wherein optionally a signal peptide is attached to the amino terminus of said coagulation factor, wherein at least one CTP is optionally attached to the coagulation factor via a linker, and wherein said coagulation factor is selected from Factor VII (FVII) and activated Factor VII (FVIIa). 13. The method of claim 12, wherein the sequence of at least one CTP is selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2. 14. The method of claim 12, wherein at least one CTP is glycosylated. 15. The method of claim 12, wherein at least one CTP is truncated. 16. The method of claim 12, wherein said linker is a peptide bond. 17. The method of claim 12, wherein the sequence of said CTP-modified Factor VII (FVII) or activated Factor VII (FVIIa) is set forth in SEQ ID NO: 46. 18. The method of claim 12, wherein said polypeptide has a signal peptide. 19. The method of claim 18, wherein said signal peptide is set forth in SEQ ID NO: 47. 20. The method of claim 18, wherein the sequence of said CTP-modified FVII is set forth in SEQ ID No: 25. 21. The method of claim 12, wherein said activated FVII (FVIIa) polypeptide is in the form of a disulfide-linked two chain heterodimer, wherein said two chains comprise a light chain consisting of amino acids 1-152 and a heavy chain consisting of amino acids 153-490 of SEQ ID NO: 46. 22. A method of improving the area under the curve (AUC) of a coagulation factor, comprising the step of attaching three to five chorionic gonadotropin carboxy terminal peptides (CTPs) to the carboxy terminus of said coagulation factor, thereby improving the AUC of said coagulation factor, wherein optionally a signal peptide is attached to the amino terminus of said coagulation factor, wherein at least one CTP is optionally attached to the coagulation factor via a linker, and wherein said coagulation factor is selected from Factor VII (FVII) and activated Factor VII (FVIIa). 23. The method of claim 22, wherein the sequence of at least one CTP is selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2. 24. The method of claim 22, wherein at least one CTP is glycosylated. 25. The method of claim 22, wherein at least one CTP is truncated. 26. The method of claim 22, wherein said linker is a peptide bond. 27. The method of claim 22, wherein the sequence of said CTP-modified Factor VII (FVII) or activated Factor VII (FVIIa) is set forth in SEQ ID NO: 46. 28. The method of claim 22, wherein said polypeptide has a signal peptide. 29. The method of claim 28, wherein said signal peptide is set forth in SEQ ID NO: 47. 30. The method of claim 29, wherein the sequence of said CTP-modified FVII is set forth in SEQ ID No: 25. 31. The method of claim 22, wherein said activated FVII (FVIIa) polypeptide is in the form of a disulfide-linked two chain heterodimer, wherein said two chains comprise a light chain consisting of amino acids 1-152 and a heavy chain consisting of amino acids 153-490 of SEQ ID NO: 46. 32. A method of reducing the dosing frequency of a coagulation factor, comprising the step of attaching three to five chorionic gonadotropin carboxy terminal peptides (CTPs) to the carboxy terminus of said coagulation factor, thereby reducing the dosing frequency of said coagulation factor, wherein optionally a signal peptide is attached to the amino terminus of said coagulation factor, wherein at least one CTP is optionally attached to the coagulation factor via a linker, and wherein said coagulation factor is selected from Factor VII (FVII) and activated Factor VII (FVIIa). 33. The method of claim 32, wherein the sequence of at least one CTP is selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2. 34. The method of claim 32, wherein at least one CTP is glycosylated. 35. The method of claim 32, wherein at least one CTP is truncated. 36. The method of claim 32, wherein said linker is a peptide bond. 37. The method of claim 32, wherein the sequence of said CTP-modified Factor VII (FVII) or activated Factor VII (FVIIa) is set forth in SEQ ID NO: 46. 38. The method of claim 32, wherein said polypeptide has a signal peptide. 39. The method of claim 38, wherein said signal peptide is set forth in SEQ ID NO: 47. 40. The method of claim 39, wherein the sequence of said CTP-modified FVII is set forth in SEQ ID No: 25. 41. The method of claim 32, wherein said activated FVII (FVIIa) polypeptide is in the form of a disulfide-linked two chain heterodimer, wherein said two chains comprise a light chain consisting of amino acids 1-152 and a heavy chain consisting of amino acids 153-490 of SEQ ID NO: 46.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Lee, Dong-Eok; Oh, Myung-Suk; Kim, Ki-Wan; Chung, Bo-Sup; Ha, Byung-Jhip; Park, Ji-Sook, Fusion protein having the enhanced in vivo activity of erythropoietin.
DeFrees, Shawn; Zopf, David A.; Bayer, Robert J.; Hakes, David James; Bowe, Caryn L.; Chen, Xi, Glycopegylation methods and proteins/peptides produced by the methods.
Wands Jack R. (Waban MA) Zurawski ; Jr. Vincent R. (West Chester PA) Schoemaker ; Hubert J. P. (Newton MA), Immunoassay utilizing monoclonal high affinity IgM antibodies.
Smulson Mark E. (Washington DC) Bhatia Kishor (Arbutus MD) Huppi Konrad (Reston VA), Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for hu.
Klima,Horst; Lehmann,Paul; Roeddiger,Ralf; Walter Matsui,Ruth, Method of treating disturbances of iron distribution in inflammatory intestinal diseases.
Martinez, Alexa L; Sherman, Merry R; Saifer, Mark G. P.; Williams, L. David, Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof.
Boime Irving ; Menahem David Ben, Single chain glycoprotein hormones comprising two .beta. and one .alpha. subunits and recombinant production thereof.
Mark David F. (Danville CA) Lin Leo S. (Fremont CA) Yu Lu Shi-Da (Oakland CA), Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins.
Selden Richard F. ; Borowski Marianne ; Gillispie Frances P. ; Kinoshita Carol M. ; Treco Douglas A. ; Williams Melanie D., Tranfected human cells expressing human .alpha.-galactosidase A protein.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.